We are seeking investors for an investigator-initiated study to develop a novel platform technology.

We are seeking licensees for a portfolio of assets that target hard-to-treat oncology driving proteins LMO2 and RAS.

We're seeking commercial partners to exploit a novel method of analysing whole-body diffusion-weighted MRI (WBDWI) data collected using routine clinical imaging protocols.

We're seeking a collaborative partner for the licensing and co-development of FUME-TCRseq, a new accurate and and low-cost tool for genomic analysis of the T-cell receptor.

We're seeking licensee or commercial partner to continue the development of a highly potent and orally bioavailable inhibitor of MPS1, CCT289346.

We're seeking partners to continue the development of a new ultrasound-based imaging technique that can visualise and measure the stiffness of tumours.

We're seeking partners to continue the development of a cancer biomarker (HORMAD1) for predicting susceptibility to drugs targeting cell division, including spindle checkpoint and kinetochore error correction inhibitors.

We're seeking a collaborative partner to accelerate the development of an ERAP1 programme in the Centre for Cancer Drug Discovery, with a particular potential to enhance the effectiveness of checkpoint inhibitors or radiotherapy, in patients who do not currently respond to those treatments.

We're seeking a commercial partner to support the development of a new test for predicting future cancer risk in patients with inflammatory bowel disease (IBD).

We're seeking commercial partners to exploit a synthetic lethal interaction between EXD2 and cancers with deficiencies in homologous recombination, including mutations in BRCA1 or BRCA2.

We're seeking commercial partners to support the clinical transition of a project which aims to target ART1, a novel immune checkpoint, for the treatment of lung cancer, to achieve maximum patient benefit.

We're seeking licensees or collaborators for an AI-based method that could help accelerate research into how different cell types within the tumour microenvironment influence tumour behaviour, prognosis and response to treatment.

We're seeking a partner to continue the development of a colorectal cancer gene signature as a clinical test for predicting therapy response (e.g. anti-EGFR therapies, including monoclonal antibodies).

We're seeking partners to continue the development of a gene expression signature into a predictive biomarker for predicting prognosis and treatment response for patients with early-stage ER+/HER2+ breast cancer.

We are seeking partners to continue the development of a gene expression signature for predicting tumour response to the multi-target tyrosine kinase inhibitor pazopanib and support its transition to the clinic.

We are seeking a partner to continue the development of CAR-T technology targeted against transmembrane glycoprotein Endosialin in breast cancer and other solid tumours.

We are seeking a partner to continue the commercial development of AI-TIL: an image-based biomarker that quantifies tumour-infiltrating lymphocyte (TIL) from histopathological samples using proprietary AI technologies.

We're seeking a partner to collaborate on the development of anti-cancer vaccines and/or immunotherapeutic approaches to help overcome resistance to PARP inhibition or platinum-based chemotherapy

We are seeking a partner to continue the development of IL-23 inhibitors in advanced, castration resistant prostate cancer following the surprising discovery that IL-23 secreted by myeloid suppressor cells confers resistance to androgen deprivation therapy.

We are seeking a partner to continue the development of ARID1A and other BAF-complex genes as cancer biomarkers for predicting sensitivity to ATR inhibitors.

We are seeking a partner to continue the development of a gene expression profiling method for predicting response to radiotherapy in muscle invasive bladder cancer.

We're seeking a partner to to continue the development of a breast cancer gene signature for predicting resistance/sensitivity to aromatase inhibitors and/or CDK4/6 inhibitors.